Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2022-10-27 Major Shareholding Noti…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Change in substantial holding 4 pages 185.2KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 under the Corporations Act 2001, Section 671B, which is a Notice of change of interests of a substantial holder. It details changes in voting power and shareholdings of substantial holders over specific dates, including acquisitions by subscription and institutional private placements. This type of filing is a notification of changes in significant share ownership levels, not a financial report or other corporate filing type. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and content confirm it is not a brief announcement or a report publication notice but a substantive notification of shareholding changes.
2022-10-27 English
Notice of Annual General Meeting/Proxy Form 22 pages 435.1KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF 2022 ANNUAL GENERAL MEETING AND EXPLANATORY STATEMENT OF PHARMAXIS LTD' and details the arrangements for the 2022 Annual General Meeting (AGM) including date, time, virtual meeting instructions, proxy voting instructions, and the agenda items such as adoption of remuneration report, re-election of directors, and approval of share placements and option grants. It includes resolutions to be voted on at the AGM and instructions for shareholders. The document is a notice and explanatory statement for the AGM, not the actual AGM materials or minutes. It is not a full annual report or financial report but a meeting notice and proxy solicitation document. Therefore, it fits the category of AGM Information (AGM-R). The document length is substantial and contains detailed meeting information, consistent with an AGM notice and explanatory statement.
2022-10-27 English
Annual Report to shareholders 72 pages 1.2MB
Annual Report Classification · 100% confidence The document is titled 'Statutory Annual Report 2022' and mentions lodging with the Australian Securities Exchange and the Australian Securities and Investments Commission. It refers to consolidated financial statements and contains detailed financial and corporate information typical of a full annual report. The length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2022-10-27 English
Appendix 4G 14 pages 190.2KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G' and references the ASX Listing Rules, specifically Listing Rule 4.10.3 and 4.7.4, which pertain to corporate governance disclosures. It includes a key to disclosures related to the Corporate Governance Council Principles and Recommendations. The document states that the corporate governance statement is available on the company's website and is approved by the board. The Appendix 4G is described as a verification tool for compliance with corporate governance disclosure requirements and is lodged alongside the annual report. The document does not contain the full corporate governance statement itself but rather serves as a structured disclosure checklist and confirmation of compliance. This type of document is regulatory in nature, fulfilling listing rule requirements, and is not the full annual report or a management report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for compliance and regulatory announcements that do not fit other specific categories.
2022-10-27 English
Corporate Governance Statement 19 pages 194.0KB
Governance Information Classification · 100% confidence The document is titled 'Copy of Corporate Governance Statement – 2022' and discusses the company's corporate governance framework, board structure, policies, and practices in detail. It references the ASX Corporate Governance Principles and Recommendations and includes information about board composition, director independence, committee charters, and performance evaluations. There is no financial data, earnings information, or audit results presented. The content aligns with a report detailing the company's internal rules, board structure, and governance practices. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement or summary.
2022-10-27 English
Becoming a substantial holder 3 pages 88.8KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 Notice of Initial Substantial Holder filed under the Corporations Act 2001, Section 671B. It details the substantial shareholding of Regal Funds Management Pty Ltd and its associates in Pharmaxis Ltd, including voting power, relevant interests, and acquisition details. This type of filing is a notification of a major shareholding change, specifically the crossing of a substantial ownership threshold. It is not a financial report, management announcement, or other types of filings. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and content confirm it is the actual notification, not just an announcement or reference to another report.
2022-10-27 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.